| General Information | |
|---|---|
| ZINC ID | ZINC000049762353 |
| Molecular Weight (Da) | 560 |
| SMILES | O=C(c1nn(-c2ccc(Cl)cc2Cl)c(-c2ccc(Br)cc2)c1Cn1cncn1)N1CCCCC1 |
| Molecular Formula | C24Br1Cl2N6O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 141.127 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 34 |
| LogP | 5.235 |
| Activity (Ki) in nM | 5.1286 |
| Polar Surface Area (PSA) | 68.84 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.074 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.25 |
| Ilogp | 3.85 |
| Xlogp3 | 5.82 |
| Wlogp | 5.49 |
| Mlogp | 4.61 |
| Silicos-it log p | 4.63 |
| Consensus log p | 4.88 |
| Esol log s | -7.06 |
| Esol solubility (mg/ml) | 0.0000484 |
| Esol solubility (mol/l) | 8.65E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.04 |
| Ali solubility (mg/ml) | 0.0000515 |
| Ali solubility (mol/l) | 0.00000009 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.51 |
| Silicos-it solubility (mg/ml) | 0.00000172 |
| Silicos-it solubility (mol/l) | 3.07E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.59 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.56 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.996 |
| Logd | 4.202 |
| Logp | 4.97 |
| F (20%) | 0.002 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 96.62% |
| Vdss | 1.276 |
| Fu | 5.28% |
| Cyp1a2-inh | 0.414 |
| Cyp1a2-sub | 0.144 |
| Cyp2c19-inh | 0.898 |
| Cyp2c19-sub | 0.094 |
| Cl | 4.851 |
| T12 | 0.072 |
| H-ht | 0.288 |
| Dili | 0.983 |
| Roa | 0.801 |
| Fdamdd | 0.268 |
| Skinsen | 0.543 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.134 |
| Bcf | 1.956 |
| Igc50 | 4.702 |
| Lc50 | 6.305 |
| Lc50dm | 4.13 |
| Nr-ar | 0.009 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.872 |
| Nr-aromatase | 0.982 |
| Nr-er | 0.235 |
| Nr-er-lbd | 0.017 |
| Nr-ppar-gamma | 0.055 |
| Sr-are | 0.891 |
| Sr-atad5 | 0.044 |
| Sr-hse | 0.411 |
| Sr-mmp | 0.75 |
| Sr-p53 | 0.636 |
| Vol | 476.353 |
| Dense | 1.171 |
| Flex | 0.207 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.306 |
| Synth | 2.622 |
| Fsp3 | 0.25 |
| Mce-18 | 63 |
| Natural product-likeness | -1.801 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |